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Exon 1 of the HD Gene with an Expanded
CAG Repeat Is Sufficient to Cause a Progressive
Neurological Phenotype in Transgenic Mice
Laura Mangiarini,1 Kirupa Sathasivam,1 Mary Seller,1 The onset of symptoms is generally in midlife although
Barbara Cozens,7 Alex Harper,2 Colin Hetherington,3 it can range from early childhood to >70 years. Anticipa-
Martin Lawton,4 Yvon Trottier,5 Hans Lehrach,6 tion is observed, predominantly when the disease is
Stephen W. Davies,7 and Gillian P. Bates1 inherited through the male line, with the result that 70%
1Division of Medical and Molecular Genetics of juvenile cases inherit the disease from their father.
UMDS The symptoms have an emotional, motor, and cognitive
Guy’s Hospital component. A detailed description of all aspects of HD
London SE1 9RT can be found in Harper (1991). Chorea is a characteristic
United Kingdom feature of themotor disorder and is defined as excessive
2UMDS Transgenic Unit spontaneous movement, irregularly timed, randomly
The Rayne Institute distributed, and abrupt. It can vary from being barely
St. Thomas’s Hospital perceptible to extremely severe. It involves all parts of
London SE1 7EH the body, can have repetitive and stereotypic elements,
United Kingdom and may have a pseudopurposive appearance (Harper,
3Biomedical Services 1991). Other frequently observed motor abnormalities
John Radcliffe Hospital include dystonia (sustained muscle contraction), rigid-
University of Oxford ity, bradykinesia (abnormally slow movements), oculo-
Oxford OX3 9DU motor dysfunction, and tremor. Cerebellar dysfunction,
United Kingdom upper motorneuron abnormalities, epilepsy, and myo-
4Biological Services Division clonus (brief shock-like muscle jerks) are rare except
UMDS in the juvenile form of the disease, which commonly
Guy’s Hospital presents with a “Parkinsonlike rigidity.” Voluntary move-
London SE1 9RT ment disorders include fine motor incoordination, dys-
United Kingdom arthria (impairment of articulation), and dysphagia (diffi-
5 Institut de Genetique et Biologie Moleculaire culty in swallowing).The emotionaldisorder is commonly
et Cellulaire
depression and irritability, and the cognitive component
CNRS/INSERM/ULP comprises a subcortical dementia. The biochemical ba-
Illkirch




The HD mutation results in the expansion of a polyglu-6Max Planck Institut fur Molekulare Genetik
tamine (polygln) tract in a large 350 kDa protein of un-Dahlem, Berlin D14195
known function (Huntington’s Disease Collaborative Re-Germany
search Group, 1993). The normal and expanded HD7Department of Anatomy and Developmental Biology
allele sizes have been defined as CAG6–37 and CAG35–121University College
repeats, respectively. An inverse correlation betweenLondon WC1E 6BT
age of onset and repeat length is most pronounced forUnited Kingdom
juvenile HD for which the longest repeats have been
observed (Huntington’s Disease Collaborative Research
Group, 1993; Telenius et al., 1993). Despite the selectiveSummary
cell death, the HD transcript is ubiquitously expressed
(Strong et al., 1993). The polyglutamines are success-Huntington’s disease (HD) is one of an increasing num-
fully translated and the huntingtin protein (htt) productsber of neurodegenerative disorders caused by a CAG/
arising from expanded alleles have been identified inpolyglutamine repeat expansion. Mice have been gen-
protein extracts from HD patients (Jou and Myers, 1995;erated that are transgenic for the 59 end of the human
Trottier et al., 1995a).HD gene carrying (CAG)115–(CAG)150 repeat expansions.
CAG/gln expansion has been found to be the caus-In three lines, the transgene is ubiquitously expressed
ative mutation in five neurodegenerative diseases forat both mRNA and protein level. Transgenic mice ex-
which the gene has been cloned. In addition to HD, thesehibit a progressive neurological phenotype that exhib-
include spinal and bulbar muscular atrophy (SBMA) (Laits many of the features of HD, including choreiform-
Spada et al., 1991), spinocerebellar ataxia type 1 (SCA1)like movements, involuntary stereotypic movements,
(Orr et al., 1993), dentatorubral-pallidoluysian atrophytremor, and epileptic seizures, as well as nonmove-
(DRPLA) (Koide et al., 1994), and Machado Joseph dis-ment disorder components. This transgenic model will
ease (MJD or SCA3) (Kawaguchi et al., 1994). Manygreatly assist in an eventual understanding of the mo-
aspects of the genetics and molecular biology are com-lecular pathology of HD and may open the way to the
mon to these diseases. They are autosomal dominanttesting of intervention strategies.
(with the exception of X-linked SBMA) and show varying
degrees of anticipation on paternal transmission. TheIntroduction
size of the normal and expanded CAG repeat ranges
are comparable, and available data indicate that age ofHuntington’s disease (HD) is an autosomal dominant
progressive neurodegenerative disorder (Harper, 1991). onset correlations and patterns of repeat stability are
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reproduced. A similar ubiquitous expression pattern is gene or in isolation, is toxic to Purkinje cells and causes
a corresponding ataxic phenotype.also characteristic, and the presence of the expanded
forms of ataxin-1 (SCA1 protein) and atrophin-1 (DRPLA In our intitial attempt to generate a murine model of
HD, we have focused on the construction of a mutantprotein) in lysates from patient tissues have been ob-
served (Servadio et al., 1995; Yazawa et al., 1995). yeast artificial chromosome (YAC) for introduction by
pronuclear injection. Progress was severely hamperedDespite the otherwise apparent universality of this
mutation, the patterns of cell death differ between these by both instability of YAC intermediates and the severe
instability of highly expanded CAG repeats in yeast.diseases. In HD, the most striking atrophy occurs in the
caudate nucleus, which is often reduced to a rim of Consequently, to address the question of CAG repeat
stability in the mouse, transgenic lines were establishedtissue. The putamen and globus pallidus also undergo
atrophy, and there are subtle changes in the cerebral with a 1.9 kb human genomic fragment containing pro-
moter sequences and exon 1 carrying expansions ofcortex (Vonsattel et al., 1985). SBMA is a form of motor
neuron disease with both spinal and bulbar motor neu- approximately (CAG)130. Unexpectedly, this fragment has
been sufficient to generate a progressive neurologicalron involvement (Kennedy et al., 1968). The SCA1 and
SCA3 spinocerebellar ataxias are clearly distinguished phenotype that displays many of the characteristics of
HD. This is the first time that a model of one of theseby major neuropathological features: Purkinje cell, pon-
tine nuclei, and inferior olivary nuclei degeneration in diseases has beengenerated by a transgene driven from
an endogenous promotor. The availability of a mouseSCA1 (Zoghbi et al., 1993) and pontine nuclei and the
molecular layer of the cerebellum in SCA3 (Durr et al., model of the disease is extremely informative with re-
gard to the size of the polygln expansion and level of1996). In DRPLA, neuropathology includes the cerebellar
dentate nucleus, globus pallidus, red and subthalamic expression required to produce a phenotype with a
given age of onset in the mouse. This work suggestsnuclei, Purkinje cells, brain stem tegmentum, and the
lateral corticospinal tract (Takahashi et al., 1988). The that the polygln-containing domain of the htt protein
may be sufficient to generate a mouse model of HD.proteins containing the polygln repeats are otherwise
unrelated. In SBMA, the repeat lies within the androgen
receptor (La Spada et al., 1991), while the others are in Results and Discussion
novel genes of unknown function. Subcellular localiza-
tion suggests differing roles for these proteins (DiFiglia Fragment Used for Transgenesis
et al., 1995; Servadio et al., 1995; Trottier et al., 1995a; The microinjection fragment was a 1.9 kb SacI–EcoRI
Yazawa et al., 1995). fragment from the 59 end of the human HD gene isolated
It isessential that transgenic models of these diseases from a phage genomic clone derived from an HD patient
are developed. There have been two previous reports (Figure 1a). It is composed of z1 kb of 59 UTR se-
of a neurological phenotype observed in mice trans- quences, exon 1 carrying expanded CAG repeats of
genic for a protein carrying a polygln repeat expansion. z130 units and the first 262 bp of intron 1. As the CAG
The first used a SCA1 cDNAconstruct with (CAG)82 under repeats are unstable when propagated in E. coli, the
the control of a Purkinje cell specific promoter (Burright DNA preparation used for microinjection contained a
et al., 1995). Three heterozygous lines overexpressing heterogeneous set of repeats of varying size but of the
the SCA1 transcript by 10- to 100-fold and two homozy- order of 130 units. In the event that an unspliced mRNA
gous lines showed a progressive ataxic phenotype be- should be transcribed from this fragment, an “in-frame”
tween 12 and 26 weeks of age. The mice became clearly stop codon immediately at the beginning of intron 1
ataxic when walking and routinely fell when attempting would result in a truncated protein corresponding to the
to stand on their hind legs. Pathologic examination first 90 amino acids of the published htt protein (repeat
showed significant loss of the Purkinje cell population size of (CAG)21).with Bergmann glial proliferation and shrinkage and glio-
sis of the molecular layer. More recently, transgenic
Genomic Organization of the Integration Eventsmice have been reported with a (CAG)79 version of the
Transgenic mice were generated by microinjection ofSCA3 gene and also the (CAG)79 polygln tract in isolation,
single cell CBAxC57BL/6 embryos. Of 29 newborn mice,both under the control of the Purkinje cell specific pro-
seven died neonatally, and of the remaining 22 pups,moter (Ikeda et al., 1996). Affected mice transgenic for
one male was transgenic. This founder (R6) was initiallythe isolated polygln tract were severly ataxic, they ex-
backcrossed to both C57BL/6 and to CBAxC57BL/6 fe-hibit a wide-based hind limb stance, frequently fall when
males. However, a subsequent need to optimize littermoving, and are unable to rear. Overt Purkinje cell death
size has resulted in the maintenance of the transgenewas observed with secondary effects to the molecular
on the CBAxC57BL/6 hybrid background. F1 mice wereand granular cell layers. No phenotype was observed
genotyped both by Southern analysis and by PCR toin the mice transgenic for the entire mutated SCA3 gene.
determine the CAG repeat size. Figure 1b shows aThe authors suggested that the polygln tracts are more
Southern blot of BamHI digested DNA from a numbertoxic in isolation than in the context of a protein, al-
of F1 progeny. It was possible to deduce that the micro-though in the absence of any information concerning
injection fragment had integrated into five different re-transgene copy number, genomic structure of the inte-
gions of the founders’ genome. The predicted genomicgration sites, or expression levels, this interpretation
organization of the integration events is illustrated inshould be treated with caution. These reports have
Figure 1c. In lines R6/1 and R6/0, the fragment hasshown that Purkinje cell specific overexpression of an
expanded polygln tract, both in the context of the SCA1 integrated as an intact single copy, and in line R6/T as
Huntington’s Disease Transgenic Mice
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Figure 1. Microinjection Fragment and Iden-
tification of the Integration Events
(a) Restriction map of the human genomic
fragment used for microinjection. An arrow
denotes the transcription start site and aster-
isk indicates the position of an in-frame stop
codon at the beginning of intron 1. 4G6SN0.3
and 4G6PE0.2 are fragments used as hybrid-
ization probes, and solid triangles indicate
the location of PCR assays used for genotyp-
ing and RNA analysis.
(b) Southern blot of genomic DNA from the
R6 founder and a number of F1 progeny. DNA
was digested with BamHI and probed with
4G6PE0.2. The genotypes are indicated
above the lanes (1, 2, 0, T, or 5). A plus sign
indicates that the mouse also scored as
transgenic when typed with the CAG repeat
PCR assay. BamHI fragment sizes are as fol-
lows: R6/1, 20.0 kb; R6/2, 1.9 and 0.8 kb; R6/
5, 6.0, 3.6, 2.5, 2.3, and 1.9 kb; R6/0, band
migrates close to slot (S); R6/T, 6.0 kb. The
R6/T genotype is negative with the CAG re-
peat PCR assay.
(c) Genomic organisation of the integration
sites of the transgenes. R6/0, R6/1, and R6/
T are single copy integrants although R6/T is
highly deleted. R6/2 probably originated as a
three copy integrant, the flanking fragments
having undergone deletions. (asterisk) It has
not been possible to completely resolve the
structure of the R6/5 integration event. Three
of the five BamHI fragments can be ac-
counted for by the structure as drawn.
a highly truncated fragment. In line R6/0, the fragment configuration, as in those illustrated, or by simple dele-
tions. It seems likely, therefore, that a complicated re-has most probably inserted adjacent to a repetitive ge-
nomic structure.When the probe4G6PE0.2 is hybridized arrangement must have occurred for which it has not
been possible to completely unravel the genomicto Southern blots of transgene genomic DNA digested
with BamHI, SmaI, PstI, or NcoI, in each case a band is structure.
detected that has barely migrated into the gel. If the
same blots are probed with 4G6SN0.3, the 59UTR probe,
bands of a more expected size range are seen. Line R6/ Size of the CAG Expansion in Each
of the Transgenic Lines2 most probably originated as a three copy integration
event, the flanking fragments having been subject to Four of the transgenic lines: R6/0, R6/1, R6/2, and R6/
5 carry expanded CAG repeats. The size of the expan-deletions, with the result that this transgene functions
essentially as a single copy integrant. Finally line R6/5 sion was determined by PCR amplification of the repeat
using a fluorescently labeled primer and subsequentis represented by five bands on a BamHI Southern blot.
It is clear that four fragments have integrated as illus- size determination using an ABI sequencer (Figure 2).
The peak sizes are as follows: R6/1, 116 repeat units;trated in Figure 1c. This includes both a tail-to-tail and
head-to-head arrangement. However, other hybridiza- R6/0, 142 repeat units; R6/2, 144 repeat units. Line R6/5
is more complicated with peaks at 128, 132, 135, 137,tion bands could not be explained by a straightforward
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Figure 2. Measurement of the Size of the
CAG Expansion in the R6 Transgenic Lines
The CAG repeats were amplified with a FAM-
labeled primer as described. The top panel
shows the trace specific to the founder (R6)
and the four lowerpanels, thetraces obtained
in F1 mice with the R6/0, R6/5, R6/2,and R6/1
genotypes.
and 156 repeat units. These repeat sizes are consider- the other containing the R6/1, R6/2 and R6/5 trans-
genes.ably larger than those that have generally been reported
to cause the juvenile form of HD in humans. Both ga-
metic and somatic repeat instability have been observed Phenotype Observed in the R6/2
(manuscript submitted). Transgenic Line
The age of onset in line R6/2 has been observed as early
as four weeks (one mouse) but most frequently occursSegregation of the Integration Events
The specific genotype frequencies found in 321 F1 mice between nine and eleven weeks. Age at death has gener-
ally been between 10 and 13 weeks although the mousederived from the R6 founder are summarized in Table
1. The integration events appear to segregate indepen- with the age of onset at four weeks died at six and a
half weeks. The mice display a progressive neurologicaldently but are only seen in certain combinations. The
founder is therefore a germ line chimera with one set of phenotype. As far as can be ascertained, the mice re-
main alert, exploratory and inquisitive, and responsivegerm cells containing the R6/0 and R6/T transgenes and
Huntington’s Disease Transgenic Mice
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Characteristic vocalizations have been observed.Table 1. Frequency of Genotypes Arising in 321 F1 Progeny
These include a sound similar to that made by a new
Genotype N
born litter, which resembles teeth chattering from cold,
R6/0 56 but is likely to have a respiratory basis (since it occurs
R6/T 61 before the young mice have teeth). A second sound, a
R6/0 1 R6/T 62
type of chirping noise, is more reminiscent of a bird thanNegativea (56/71)
of a mouse. The mice are more likely to make these
R6/1 8 sounds when they are under stress (for example, away
R6/2 16
from the home cage).R6/5 15
The mice appear to urinate more frequently. The bed-R6/1 1 R6/2 9
ding at the front of the cage becomes excessively wetR6/1 1 R6/5 8
R6/2 1 R6/5 11 as compared to that in cages housing normal mice. They
R6/1 1 R6/2 1 R6/5 4 are unlikely to be suffering from spastic bladders as the
Negativea (15/71) wetting of the bedding is not uniform. Urine tests in
a The total number of nontransgenic mice are divided between the 18 transgenic mice (11 male and 7 female) showed no
two genotype clusters in a proportion consistent with the genotype abnormality in glucose or protein levels. Similarly, blood
frequencies. tests in two mice showed glucose and protein levels to
be within the normal range.
R6/2 females are sterile and, of ten R6/2 males that
to sensory stimuli. The phenotype is complex. There are have been placed with females from a time just prior to
a number of components to the motor disorder including expected sexual maturity, five have mated. Of these,
a resting tremor, movements described as resembling one mouse produced one litter, two mice produced two
chorea, stereotypic involuntary movements, and in litters and two produced four litters. On autopsy, the
some cases a mild ataxia manifesting as dysmetria. One reproductive organs consistently appear vestigial or at-
of the first symptoms is a dyskinesia of the limbs when rophied. Females often have miniscule ovaries and a
held by the tail. This progresses to an alternating clasp- hair-like uterus. Males have small testes, seminal ducts,
ing together and releasing of the feet until the mice clasp and coagulation glands. On histology, one male that had
their feet together immediately after they are picked up, failed to mate was found to have testicular atrophy with
(Figure 3a), and can no longer release this posture. The an absence of spermatazoa, an atropy of the epididymus
mice develop a constant tremor that becomes progres- with aspermia, and no secretion present in the coagula-
sively worse. The tremor tends to be less noticeable tion gland.
when they are quiet or asleep, but worsens under stress The mice die suddenly and the cause of death is gen-
(for example, the removal of the cage lid) or if they reach erally unknown although one mouse was observed to
for food or to climb out of the cage. As the disorder die during an epileptic seizure.
progresses, stereotypic involuntary movements are ap-
parent, which include repetitive stroking of the nose and
face, and a hind limb kicking/scratching motion. Sudden Dosage Effect on Age of Onset and Phenotype
Severity in Complex Genotypesmovements that involve the whole body and may resem-
ble chorea are observed. These are rapid, abrupt, irregu- Lines R6/1, R6/2, and R6/5 have been established from
the founder. In the F1 generation, mice with all possiblelar, and manifest as a shaking/shudder of the trunk. The
mice do not develop a wide-based gait, can stand on combinations of these transgenes were identified. Each
aspect of the phenotype, as described for line R6/2, hastheir hind limbs and climb out of the cage without falling.
They only consistently lose balance when sitting on their been observed for the genotypes listed in Table 2. In
the end stages of the disease, the transgenes are alwayshind limbs, turning, and reaching round to groom their
backs, which results in a somersault. The mice exhibit considerably smaller than their normal littermates. The
age of onset varies from <3 weeks (R6/11R6/21R6/5severe handling-induced epileptic seizures that can last
for several minutes. genotype) to z4 or 5 months (R6/1 line).
The (R6/11R6/21R6/5) genotype is the most severe.At weaning, the R6/2 transgenes are indistinguishable
from their normal litter mates. Coincident with the onset Only four such mice were recovered in the F1 generation.
The overall genotype frequency (Table 1) would haveof motor symptoms, their weight plateaus and then pro-
gressively decreases. In the end stages, mice have been predicted more than this, and it is possible that some
mice with this genotype died neonatally or in utero. Allobserved to weigh as little as 60%–70% of their normal
sibs. As the disease becomes more severe, they are aspects of the phenotype are more severe and have a
more rapid progression. The (R6/11R6/21R6/5) micevery frequently observed to be eating but do not gain
weight. It appears that the mice are eating rather than are considerably smaller than their litter mates at wean-
ing. For example, one weighed 5.2 g at 23 days of agejust breaking off food. Their food comprises an ex-
panded chow, which does not crumble easily, and ex- as compared to a mean of 9.2 g for her female sibs. She
reached a maximum weight of 7.5 g but was only 6.0 gcess food crumbs are not observed in the bedding. On
autopsy, the mice are often emaciated with an overall at death at 51 days as compared to a mean of 16.3 g
for her sibs. In contrast, line R6/1 has the latest age ofloss of muscle bulk although food is observed in the
stomach and fecal pellets in the gut. Histological analy- onset and the slowest progression. The mice begin to
exhibit the feet-clasping posture when suspended bysis of muscle samples showed no evidence of a my-
opathy. the tail at z4–5 months. At between 6 and 7 months,
Cell
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Figure 3. Comparison of R6 Transgenic Mice
and Littermate Controls
(a) An R6/2 transgenic mouse demonstrating
the feet-clasping posture adopted when sus-
pended by the tail. The normal mouse holds
its hind limbs outward inorder to steady itself.
(b) The R6/2 mouse (17.7 g) and normal lit-
termate (21.3 g) at 12 weeks of age. The
transgenic mouse is thinner.
(c) An R6/11R6/2 (10.1 g) transgenic mouse
and normal littermate (19.6 g) at seven weeks,
three days. There is a considerable size dif-
ference.
some show a mild tremor and intermittently exhibit all no obvious cell death was the only consistent observa-
tion resulting from a routine histopathological examina-aspects of the involuntary movement disorder as de-
scribed for the R6/2 line. Epileptic seizures have also tion (two R6/2 and six R6/11R6/5 mice in the end stages
of the disease and displaying all aspects of the pheno-been observed. The effect of transgene dosage on the
size of the mice is illustrated in Figure 3. type). Thymic atrophy is sometimes present, more fre-
quently in the more severely affected lines, but this doesOn autopsy, atrophy or gross atrophy of the primary
and secondary reproductive organs is routinely ob- not correlate with the presence or absence of pheno-
typic features. In a few mice there is a slight deformationserved. Otherwise, hepatic changes in the form of poly-
ploid hepatic nuclei and a loss of cytoplasmic mass with to the cranial vault resulting in a boney ridge over the
Huntington’s Disease Transgenic Mice
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Table 2. Comparison of the Onset and Duration of the Phenotype Associated with the R6 Genotypes
Age of Onset Age at Last Litter Age at Death
R6/1 1 R6/2 1 R6/5 , 3 weeks N/A 4–7 weeks
R6/1 1 R6/2 3–4 weeks N/A 6–8 weeks
R6/2 1 R6/5 6–7 weeks N/A 8–12 weeks
R6/2 9–11 weeks 6–9 weeksa (5 males) 10–13 weeks
R6/1 1 R6/5 12–16 weeks 12 weeksa (1 male) 24–36 weeks
R6/1 15–21 weeks 14 weeksb (1 male) 32–40 weeksc
a Mice bred continuously.
b Mouse failed to breed when cross set up at 19 weeks.
c Oldest R6/1 mouse is alive at 40 weeks.
cerebellum. This has been seen more frequently in the expansions (Trottier et al., 1995b). This antibody was
used to immunoprobe Western blots of cell lysates de-lines with the more severe phenotype but has also been
observed in line R6/11R6/5. rived from a complete set of tissues from lines R6/1,
R6/2, and R6/5. A transgene-specific product was de-A phenotype has not been observed in the heterozy-
gous (R6/5)/1 or (R6/0)/1 lines, the oldest mice now tected in lines R6/2 and R6/5 in all tissues tested. Figure
5 shows the Western blots obtained for a subset ofbeing z14 months. R6/5 homozygotes are developing
symptoms at z9 months, and the R6/5 transgene clearly tissues from lines R6/2 and R6/5. The predicted size of
the R6/2 protein would be z23 kDa. The migration ofcontributes to the onset and progression of the disorder
when in combination with R6/1 or R6/2 transgenes. the R6/2 and R6/5 products, ata size larger than this with
respect to the markers, is consistent with the aberrant
migration observed for the expanded polygln containingExpression of the Transgene
htt, ataxin-1, and atrophin-1 products when comparedPCR primers specific to exon 1 of the human HD gene
to their normal counterparts. A constant band detectedwere used to examine the expression and tissue distri-
in all transgene and control tissues was found to be duebution of the transgenes. RT–PCR showed the trans-
to cross-reactivityof theantimouse secondaryantibody.gene to be expressed in every tissue examined for lines
Comparison of the intensity of the the constant bandR6/2 (Figure 4a), R6/1, and R6/5, but was not expressed
between the R6/2 and R6/5 tissues suggests that thein line R6/0. This ubiquitous pattern of expression for
transgene protein is present at similar levels in thesethree of the lines suggests that the transgene is most
lines. A protein product has not been detected in linelikely expressed from promoter sequences present on
R6/1 despite testing ranges of polyacrylamide concen-the microinjection fragment. The absence of expression
tration and antibody dilution. It would be extremely un-in line R6/0 is probably due to a position effect as South-
likely that a protein product were not present in this line.ern analysis of this line predicts that the R6/0 transgene
One possible explanation is that the length of polyglnhas integrated adjacent to a genomic region of unusual
tract in the R6/1 protein does not present an epitope tostructure. Northern analysis revealed transcripts of 2.5
the 1C2 antibody. It is not clear from expression analysisand 2.3 kb in lines R6/1 and R6/2, respectively (Figure
why the R6/5 phenotype should be so much milder than4b) and the suggestion of a larger R6/5 transcript. The
that observed in lines R6/2 and R6/1.4G6PE0.2 probe is derived from intron 1 of the human
gene, and the presence of this sequence in the tran-
scripts indicates that the human exon 1 has not spliced Neuropathology
Nine R6/2 transgenic mice, exhibiting a broad spectrumto mouse exonic sequences potentially occurring close
to the integration sites. of severe symptoms of 2–3 weeks duration, and nine
nontransgenic littermateswere used for neuropathologi-The level of expression of the transgene with respect
to the endogenous mouse hd gene was assessed in cal investigation. Brains from the transgenic animals
were consistently smaller than controls (controls 490 6total RNA from six tissues for each of the lines R6/1,
R6/2, R6/5, and R6/0. The PCR primers had identical 9.8 mg, transgenes 395 6 8.0 mg). Serial 40 mm sections
in either the coronal (12 mice) or horizontal (6 mice)recognition sequences in exon 1 of both the mouse and
human genes and amplified mouse and human products planes were processed for either Nissl staining (Figures
6 and 7) or the immunocytochemical localization of glialof 121 and 114 bp, respectively. No expression was
detected in the R6/0 transgene. While the comparative fibrillary acidic protein (GFAP) or the mouse macro-
phage and microglial marker F4/80. The morphology ofexpression level varies between tissues, the average
expression of the R6/2, R6/1, and R6/5 transgenes was the central nervous system (CNS) in the transgenic mice
appeared normal with no focal areas of malformation or75%, 31%, and 77% of the endogenous level (data not
shown). The tissue variability made absolute quantita- neurodegeneration; however, sections of the brains of
these animals were consistently smaller than those oftion difficult, but this analysis nevertheless places the
level of expression of the transgene within the range of their litter mates (19% 6 1.6%). This reduction in size
appeared to be uniform throughout all CNS structures.the murine gene.
The monoclonal antibody, 1C2, binds specifically and Analysis of thionin-stained sections showed no evi-
dence of neuronal cell loss, oligodendrocyte loss, reac-in a size-dependent manner to pathogenic polygln
Cell
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Figure 4. mRNA Size and Expression Pattern of the R6 Transgenes
(a) RT–PCR analysis of the expression of the transgene in the R6/2
line. RNA for PCR had (1) or had not (2) been treated with RT. The
expression pattern in RNA extracted from an R6/2 transgenic mouse
(top panel) and a littermate control (bottom panel) are shown. In
each case, the first track contains RNA from human fetal brain as
a positive control.
(b) Northern analysis of the transgene expression in the R6 lines.
All lanes contained 20 mgtotal brain RNAand the blot was hybridized
with the human 4G6PE0.2 intronic probe. As expected, a signal was
not detected in the human RNA lane. Products of 2.5 and 2.3 kb
are present in the R6/1 and R6/2 lanes, respectively, and a larger
band can be seen in the R6/5 lane. Lower panel: hybridization with
the mouse GAPDH probe. The reduction in intensity in the human
RNA track is due to cross species hybridization and not unequal
loading of RNA.
tive gliosis, or inflammatory change. These latter two hippocampal gyrus, the stellate cells of layer II of the
entorhinal cortex, and the granule cells of the dentateobservations were corroborated by the GFAP and F4/
80 stained sections, where the normal distribution of gyrus were of normal size and distribution.
Basal Gangliaastrocytes and ramified microglia cells was observed in
the absence of any indication of increased reactivity of A detailed analysis of the striatum, nucleus accumbens,
globus pallidus, entopenduncular nucleus, subthalamicastrocyte staining or the presence of rounded microglia
or infiltrating macrophages. nucleus, and substantia nigra demonstrated normal
neuronal density and patterns of morphological diver-Cerebral Cortex and Hippocampus
The cytoarchitectonic structure of the cerebral cortex sity. The striatum is composed of a normal complement
of medium-sized striatal neurons interspersed withwas maintained in the frontal, temporal, occipital and
parietal lobes, although all regions were noticeably thin- fewer large and small neurons, together with satellite
glia. The white matter of the corpus callosum and thener when measured between the pia and subcortical
white matter. The large pyramidal cells of the motor fascicles of fibers forming the internal capsule contain
as many oligodendrocytes as similar sections from con-regions of the frontal cortex were present in normal
number and morphological appearance. Similarly the trol mice. The striatum is again consistently smaller in
the transgenic animals.pyramidal cells of hippocampus, subiculum and para-
Huntington’s Disease Transgenic Mice
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Figure 5. Expression Profile of the Transgene Protein Products
Identification of the transgene protein product in the R6/2 and R6/5 lines using a monoclonal antibody (1C2) that specifically detects polygln
expansions.
(a) Identification of htt in lysates prepared from lymphoblastoid cell lines from a normal individual and an HD homozygote and fractionated
on a 6% SDS–PAGE gel. The size of the respective CAG expansions are indicated above the tracts. The position at which the fibrinogen
marker (330 kDa) migrates is indicated.
(b) Lysates from an R6/2 transgene (T) and littermate control (N) were fractionated on a 10% SDS-PAGE gel.
(c) Lysates from an R6/5 transgene (T) and a litermate control were fractionated on a 10% gel.
(d) Lysates from the R6/2 and R6/5 lines fractionated on a 10% SDS–PAGE gel.
(e) The filter in (d) stripped and reprobed with the secondary antimouse antibody, which detects the constant band seen in (b)–(d).
Cerebellum and Spinal Cord The presence of human intron 1 sequences in the mRNA
rules out the possibility that the human exon splices toThe granule cells, Purkinje cells, and the neurons of the
molecular layer of the cerebellum show no differences mouse exonic sequences and therefore predicts that
the corresponding transgene protein products containfrom the control mice. Similarly, the large motor neurons
of the anterior horn of the cervical and lumbar enlarge- 69 amino acids in addition to the number of polygln
residues encoded by the repeat expansion.ments of the spinal cord and the dorsal horns are again
of normal appearance. The polygln expansions in the R6 transgenic mice are
of a size considerably greater than is generally associ-Examination of all other areas of the CNS revealed no
gross or microscopic abnormalities. ated with the juvenile form of HD. Even so, it is not
possible to predict the phenotypic expression of such
a mutation in the mouse. In HD, the major focus ofDiscussion
neuropathological change is in the striatum (part of the
basal ganglia) and the cerebral cortex. The motor disor-Transgenic mice that develop a progressive neurologi-
cal phenotype have been generated by the introduction der observed in the R6 lines is strongly suggestive of a
basal ganglia lesion. The mice exhibit involuntary jerkyof a genomic fragment containing exon 1 of the human
HD gene. Four lines have been established, with CAG shudders that have been described as resembling cho-
rea and likened to the choreic movements observed inrepeat expansions ranging from z115 to 150 repeat
units. In the three lines that exhibit a phenotype, R6/1, the neurological disease arising from canine distemper
(Lauder et al., 1954). As far as we can ascertain, choreaR6/2, and R6/5, the transgene has a ubiquitous mRNA
and protein expression pattern. The transgene mRNA has not previously been described in mice (Lyon and
Searle, 1990). The neuropathological correlate of choreais most likely transcribed from human promoter ele-
ments and extends into the flanking mouse sequences. is accepted as a basal ganglia lesion. The pronounced
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Figure 6. Nissl Sections Through the Mouse
Forebrain
Frontal section through the caudate/putamen
(cp) at the level of the lateral ventricle (v) of
a normal littermate control (A) and R6/2
transgenic mouse (B). The caudate putamen
is shown in higher power in C (control) and
D (R6/2 transgene). Scale bars, 500 mm in (A)
and (B), 80 mm in (C) and (D).
progressive resting tremor that occurs in all limbs, trunk, (Harper, 1991). It is possible that the unusual vocaliza-
tions made by theR6 transgenes arise by a similar mech-and head of affected mice also points to a basal ganglia
abnormality. The observation of epileptic seizures is anism.
A landmark study of the neuropathology of HD hascompatible with juvenile HD; however, while seizures
have a cerebral focus, they could result from many im- classified the neuropathological changes into five
grades that progress from grade 0, in which HD brainsbalances that are both intracranial or extracranial.
The R6 mice also suffer from a progressive decrease in show no gross or microscopic abnormalities consistent
with HD despite premortem symptomatology and posi-body weight and an overall lossof musclebulk. Similarly,
loss of body weight and a generalized lack of muscle tive family history, to grade 4, in which the most extreme
atrophy is observed (Vonsattel et al., 1985). The brainsbulk is a progressive and characteristic symptom of HD,
despite increased calorific intake (Sanberg et al., 1981). from the R6/2 transgenic mice were found to be on
average 19% smaller than those of their normal lit-The weight loss appears to be independent of thehyper-
kinesia and its molecular basis is not understood termates, a reduction in size that was maintained
through all CNS structures. This finding is consistent(Harper, 1991). In addition, the R6 mice appear to urinate
more frequently as judged by wetting of the bedding. with neuropathological changes occurring in HD in
which it has been noted that a 30% reduction in brainUrinary incontinence has also been noted in HD with
symptoms including frequency, urgency, nocturia, and weight in HD is associated with 20%–30% areal reduc-
tions in cerebral cortex, white matter, hippocampus,incontinence (Wheeler et al., 1985). Finally, chorea af-
fecting face, jaw, and pharyngeal muscles affects both amygdala, and thalamus (de la Monte et al., 1988). This
atrophy was similar for all grades of HD, suggesting thatspeech and swallowing and can also cause grunting and
clicking sounds that may reflect respiratory movements the shrinkage of these structures occurs early in the
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Figure 7. Nissl Sections throughout the CNS
Coronal sections through the cerebellum (A),
cerebral cortex (B), globus pallidus (C), sub-
thalamic nucleus (D), entopeduncular nu-
cleus (E) and ventral horn of the lumbar spinal
cord (F) of an R6/2 transgenic mouse. Within
the cerebellum, note the normal density of
the granule cell layer (gc), the monocellular
layer of pyramidal cells (pc) and the normal
structure of the molecular layer (m).
disease process, is not progressive, and reflects cell morphometric analysis of the R6/2 transgene brains is
merited. The neuropathological analysis of the trans-loss of both neurons as well as fibers. Interestingly,
gliosis was not readily apparent in these structures, and genes was also focused on the additional regions that
undergo neurodegeneration in the polygln expansionthe neuronal density was assessed to be normal (de la
Monte et al., 1988). In contrast, a 60% reduction in the diseases as a whole, and no evidence of localized neuro-
degeneration was identified.cross-sectional area of the caudate, putamen, and glo-
bus pallidus increases with the higher grades of HD To date, five neurodegenerative diseases have been
described that are caused by polygln expansions inbrains, indicating that these structures progressively de-
generate with prolongued survival. It is this specific pro- ubiquitously expressed unrelated proteins. It is most
probable that in each case the polygln expansion con-gressive atrophy, associated with reactive astrocytosis,
that was not apparent in the R6/2 transgenes and is fers a gain of function to the proteins and that this may
operate by a common molecular mechanism. It has beenalso absent from grade 0 HD brains (Myers et al., 1991;
Vonsattel et al., 1985). The grade 0 brains came from proposed that the specific selective cell death is di-
rected by the remainder of the respective proteins. Thepatients that had had HD symptomatology for between
2 and 13 years (Vonsattel et al., 1985; Myers et al., 1988; R6 transgene protein products contain polygln tracts
in a domain consisting of only 69 other amino acidsHedreen and Folstein et al., 1995), thereby providing no
pathological correlate for chorea and other early signs amounting to z3% of the htt protein. Therefore, the
R6 transgenic mice might be expected to represent a(Hedreen and Folstein et al., 1995). It seems likely that
the brains of the R6/2 transgenes have neuropathology generic CAG/gln disease model rather than a specific
model of HD. However, the R6 mice do not develop aconsistent with that found in the early stages of HD and
that the progression of the phenotype in these mice is pronounced ataxia as described by Burright et al. (1995)
and Ikeda et al. (1996). They do not develop a wide-so rapid that there is insufficient time for the progressive
atrophy to take place. A detailed morphometric analysis based gait or fall while moving, are able to rear, and do
not lose their righting response when turned onto theirdid uncover a neuronal loss in the caudate of grade 0
brains (Myers et al., 1991), and the absence of reactive backs. This would suggest that there is no major cere-
bellar lesion and that the R6 lines do not display theastrocytosis was taken as evidence that the neuronal
cell loss was not a recent event and may support the major movement disorder of SCA1, SCA3, and late onset
DRPLA. Similarly, they do not show a pronounced mo-hypothesis that the HD striatum is compromised from
early in development (Myers et al., 1991). A detailed torneuron disease, although the SBMA symptoms in
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humans are mild with a very slow progression and it mice are twice as old as the R6/2 mice at the onset of
the phenotype. Quantitative RNA analysis shows thewould probably be difficult to identify this component
as part of the complex R6 phenotype. The diagnosis of Hdex/6 transgene to be expressed at levels comparable
to that in the R6/2 and R6/5 lines; however, it is notHD and DRPLA was not infrequently confused before
the advent of mutation analysis afforded an unequivocal possible to use the 1C2 antibody to detect the Hdex/6
transgene protein as this is specific to polyglutaminetest. Both disorders present with complex and variable
symptoms that can include chorea, myoclonus, dysto- expansions. The Hdex lines will be bred to homozygosity
and the mice observed over the course of at least onenia, dysarthria, and seizures. Some features are more
or less associated with the juvenile or adult forms but year.
This work raises the intriguing possibility that exon 1the boundaries are not absolute. It would therefore be
difficult to express any strong claims as to the specificity of the HD gene carrying highly expanded repeats is
sufficient to generate a transgenic model of HD. Theof a mouse model with respect to these two diseases.
The R6 mice are the first transgenic model of a polygln mutation is predicted to operate by conferring a gain of
function to the mutated protein to which some cells areexpansion disease in which the transgenes are ubiqui-
tously expressed (as are the mutant human genes). The particularly sensitive. The cell-selective toxicity may
be afforded by differing compartmentalization of thetwo previous reports of a neurological phenotype ob-
served in mice transgenic for a protein carrying a polygln polygln-carrying proteins or by the specificity of their
intermolecular interactions. In order that the small R6repeat expansion used a Purkinje cell specific promoter
to drive either a SCA1 cDNA construct with (CAG)82 (Bur- transgene could initiate a chain of molecular events
comparable to those involving the entire htt protein, itright et al., 1995) or a (CAG)79 polygln tract in isolation
(Ikeda et al., 1996). Purkinje cell death was identified would be necessary to predict that the transgene occu-
pies the same subcellular localization. It has not beenwith a corresponding ataxic phenotype. It is possible
that comparable overexpression of these constructs in possible to make this comparison as our attempts at
immunohistochemistry with the 1C2 antibody have beenany other cell would also demonstrate toxicity. The dra-
matic dosage effect on the phenotype observed with consistently unsuccessful, and in addition, the subcellu-
lar localization of htt remains to some extent controver-the R6 transgenes expressing at less than endogenous
levels suggest that ubiquitous overexpression of the R6 sial. If the selectivity of the cell death arises through the
interacting proteins, the polygln-containing domain oftransgene could be lethal.
The apparent absence of specific neurodegeneration the htt protein must be sufficient to convey this specific-
ity. There may be some evidence to suggest that thisin the R6 mice supports the possibility that localized
atrophy may be secondary to a primary imbalance that could be the case, arising from the isolation of HAP1
(huntingtin associated protein 1) (Li et al., 1995). HAP1is directly responsible for the clinical symptoms that
arise in HD. Indeed, replication of the patterns of cell binds to htt containing a polygln of 21 residues, and the
association is enhanced by increasing lengths of the glndeath observed in HD by intrastriatal injections of quino-
linic acid does not cause chorea in rats (Harper, 1991). repeat. There was no binding to atrophin-1 (the mutant
protein in DRPLA) also containing 21 glutamines.It remains remarkable that the introduction of the ex-
panded version of the polygln-containing domain of htt It is impossible to predict the accuracy with which
transgenic mouse lines will model a corresponding hu-protein into transgenic mice has succeeded in reproduc-
ing not only features of the movement disorder, but also man disease. The R6 transgenes display many charac-
teristics of HD, and had this phenotype arisen in miceother aspects of the complex HD phenotype.
Two further lines of transgenic mice are required to transgenic for theentire mutant protein, the model would
have needed little justification. It is clearly possible thatdetermine the extent to which the R6 mice represent a
model of HD. First, mice transgenic for the entire HD the polygln-containing domain may be the only part of
the htt protein involved in the disease process. The R6gene carrying repeat expansions of a comparable size
must be generated. The large size of the HD gene neces- transgenic mice already provide a valuable resource
for uncovering the molecular pathology of HD and maysitates that the construct be introduced in the form of
a YAC clone (experiments in progress). An identical phe- present a target for the testing of potential therapeutic
interventions.notype would indicate that the remainder of the htt pro-
tein is superfluous to the course of the disease, and any
differences would aid in the dissection of the protein
Experimental Proceduresinto functional domains. Second, mice transgenic for
the nonexpanded CAG repeat version of the R6 lines
Genotypinghave not been described in this paper. The original pur-
DNA was prepared from tail biopsy and Southern blots and hybrid-
pose of the R6 transgenes was to study repeat stability izations were as described (Monaco et al., 1985). CAG repeats were
and, consequently, the nonexpanded controls were not sized by PCR using FAM-labeled primer 31329 (ATGAAGGCCTTC
generated in parallel. However, it is important to charac- GAGTCCCTCAAGTCCTTC) and primer 33934 (GGCGGCTGAG
GAAGCTGAGGA) in AM buffer (67 mM Tris–HCl [pH 8.8], 16.6 mMterize such mice, to rule out the unlikely scenario that
NH4SO4, 2.0 mM MgCl2 0.17 mg/ml BSA, 10 mM 2-mercaptoethanol),the phenotype observed is the result of a novel peptide.
10% DMSO, 200 mM dNTPs, 8 ng/ml primers with 0.5 U/ml TaqThree founders have now been established that contain
polymerase (Cetus). Cycling conditions were 90“ @ 948C, 25 3 (30”
the SacI–EcoRI fragment with a (CAG)18 tract: Hdex/6, @ 948C, 30“ @ 658C, 90” @ 728C), 10’ @ 728C. PCR products were
Hdex/27, and Hdex/28. F1 mice derived from the Hdex/6 sized using an ABI sequencer and the Genescan and Genotyper
founder are currently 20 weeks, and the mice show no software packages. The size of the CAG repeat was 85 bp less than
the size of the PCR product.signs of a neurological phenotype or weight loss. These
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RNA Analysis al. (1996). Spinocerebellar ataxia 3 and Machado-Joseph disease:
clinical, molecular and neuropathological features. Ann. Neurol. 39,Northern blots were prepared by standard methods and hybridized
as described (Monaco et al., 1985). RNA was reverse transcribed 490–499.
(14 U/ml MMTV RTase, BRL) in 50 mM KCl, 10 mM Tris–HCl (pH Harper, P.S. (1991). Huntington’s Disease (London: W.B. Saunders).
9.0), 0.1% Triton X-100, 6.5 mM MgCl2, 10 mM DTT, 1 mM dNTPs, Hedreen, J.C.,and Folstein, S.E. (1995). Early loss of early neostriatal
10 ng/ml random hexamers with 0.35 U/ml RNasin (Promega) at neurons in Huntington’s disease. J. Neuropath. Exp. Neurol. 54,
10’ @ 238C and then 40’ @ 378C. Primers for specific transgene 105–120.
RNA detection were 33935 (CGGCTGAGGCAGCAGCGGCTGT) and
Huntington’s Disease Collaborative Research Group (1993). A novel35093 (GCAGCAGCAGCAGCAACAGCCGCCACCGCC). PCR was in
gene containing a trinucleotide repeat that is unstable on Hunting-AM buffer, 10% DMSO, 200 mM dNTPs, 10 ng/ml primer with 0.5
ton’s disease chromosomes. Cell 72, 971–983.U/ml Taq polymerase (Cetus). Cycling conditions were 90“ @ 948C,
Ikeda, H., Yamaguchi, M., Sugai, S., Aze, Y., Narumiya, S., and34 3 (30” @ 948C, 30“ @ 688C, 90” @ 728C), 10’ @ 728C.
Kakizuka, A. (1996). Expanded polyglutamine in the Machado-
Joseph disease protein induces cell death in vitro and in vivo. NatureProtein Analysis
Genet. 13, 196–202.Frozen tissue was homogenized in 50–100 ml 50 mM Tris (pH 8.0),
Jou, Y.-S., and Myers, R.M. (1995). Evidence from antibody studies150 mM NaCl, 1% NP-40, 0.5% Deoxycholate, 0.1% SDS, and 1
that the CAG repeat in the Huntington disease gene is expressedmM 2-mercaptoethanol with 1 mM PMSF, 0.5 mM DTT, 25 mM
in the protein. Hum. Mol. Genet. 4, 465–469.benzamidine and leupeptin, pepstatin and chymostatin each at 200
ng/ml. Homogenates were sonicated on ice 10–20 s, spun at high Kawaguchi, Y., Okamoto, T., Taniwaki, M., Aizawa, M., Inoue, M.,
speed at 48C, andthe supernatant transferred to a fresh tube. Protein Katayama, S., Kawakami, H., Nakamura, S., Nishimura, M., Akiguchi,
was quantified by the Bradford assay when in sufficient quantity. I., Kimura, J., Narumiya, S., and Kakizuka,A. (1994). CAG expansions
Approximately 50 mg of protein was loaded per track onto 6% or in a novel gene for Machado-Joseph disease at chromosome
10% SDS–PAGE gels. Kaleidoscope prestained standards were 14q32.1. Nature Genet. 8, 221–228.
used as size markers (Biorad). Fibrinogen (Sigma) was added as a Kennedy, W.R., Alter, M., and Sung, J.H. (1968). Progressive proxi-
size marker of 330 kDa (Jou and Myers, 1995). Proteins were trans- mal spinal and bulbar atrophy of late onset. A sex linked recessive
ferred to PVDF membranes (Biorad) that were blocked at 48C over- trait. Neurology 18, 671–680.
night in PBS with 5% nonfat dry milk and 2% fetal calf serum.
Koide, R., Ikeuchi, T., Onodera, O., Tanaka, H., Igarashi, S., Endo,Immunoprobing with antibody 1C2 was at a 1:2000 dilution in PBS
K., Takahashi, H., Kondo, R., Ishikawa, A., Hayashi, T., et al. (1994).with 0.5% nonfat dry milk for 1 hr at RT. Washes were in PBS
Unstable expansion of CAG repeat in hereditary dentatorubral-pal-containing 1% NP-40 and 1% fetal calf serum. Secondary antibody
lidoluysian atrophy (DRPLA). Nature Genet. 6, 9–13.probing and detection was by use of the ECL kit (Amersham).
La Spada, A.R., Wilson, E.M., Lubahn, D.B., Harding, A.E., and Fisch-
beck, K.H. (1991). Androgen receptor gene mutations in X-linkedHistopathology
spinal and bulbar muscular atrophy. Nature 352, 77–79.Brains from nine R6/2 transgenes and ninenontransgenic littermates
Lauder, I.M., Martin, W.B., Gordon, E.D., Lawson, D.D., Campbell,were analyzedfor neuropathologicalchange. A 1:3 seriesof sections
R.S.F., and Watrach, A.M. (1954). A survey of canine distemper.was stained for Nissl substance with thionin, or processed free
Veterinary Record 66, 607–611.floating for the immunocytochemical localization of the glial marker,
glial fibrillary acidic protein (GFAP), or the macrophage/microglial Li, X.-J., Li, S.-H., Sharp, A.H., Nucifora, F.C., Schilling, G., Lanahan,
marker F4/80. Nuclear cells groups within the mouse brain were A., Worley, P., Snyder, S.H., and Ross, C.A. (1995). A huntingtin-
verified by reference to Sidman, Angevine, and Taber-Pierce (Sid- associated protein enriched in brain with implications for pathology.
man et al., 1971). Nature 378, 398–402.
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